Annovera (segesterone acetate and ethinyl estradiol vaginal system), a multi-use donut-shaped ring, was recently approved and presented to the Population Council by the FDA.
When the FDA approved this drug, there was an additional demand from the FDA to conduct post-marketing studies and assess the drug’s safety. Recently, a non-profit consumer advocacy group sent a petition requesting that the FDA should eliminate the drug from the U.S. pharma market since the drug shows significant risk of cardiovascular diseases.
The potential reasons behind the effect of marriage include better financial security, prompt recognition of health issues and taking right action thereby improving the overall condition of a person.
A new risk assessment tool combining gene editing technology CRISPR-Cas9 with stem cells using disease modeling techniques has been developed by a team of scientists at the Stanford University Cardiovascular Institute. The tool has facilitated the modeling of individual patients’ heart in a lab and enabled undertaking of tests to ascertain whether or not signs of diseases are displayed by cardiac cells, as per a statement by the American Heart Association.
It was great news in the field of medicine when geneticists from University of California, Los Angeles (UCLA) created a novel technique to hunt for natural hormones that would enhance cell communication to play a major role in treating obesity, diabetes and cardiovascular diseases. Scientists discovered two hormones called "notum" and "lipocalin-5", which would aid in the fat burning process. Lipocalin-5 also enhances metabolism and absorption of dietary nutrients by reducing the risk of diabetes and obesity.
The IVD sector in the country is chiefly characterized by 70 percent laboratories offering pathology services and 30 percent entities doling out radiology and imaging services. Though domestic players are flexing their muscles and are gearing to provide new-age diagnostic services with path-breaking innovations and strategic investments, multinational companies continue to hold sway over 60% of the domestic IVD market which is expected to grow by leaps and bounds in coming times.
Studies have shown that omega-3 fatty acids regulate the functioning of proteins and keeps inflammation totally under control. Still more research work is going on, in order to connect fish and cardiovascular systems in a beneficial manner.
IDx, a privately held AI diagnostics company, announced today that it has filed its De Novo submission to the FDA for IDx-DR, an AI-based system for the autonomous detection of diabetic retinopathy — a leading cause of blindness. The FDA has granted IDx-DR with a “Breakthrough Device” designation, which means the submission will receive expedited review.
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed indication based on the adequacy of the safety and benefit-risk profiles.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca (NYSE: AZN) following advancement of the drug into development. IONIS-AZ6-2.5-LRx is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH)
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.